Contents
On this page
- A single accountable content base for all audience-specific versions
- Permissible and impermissible differences between congress and regulatory decks
- Disclosure obligations specific to investor-facing decks
- Traceability of all audience-specific versions to a common source
- Coordination across medical, regulatory and investor-relations functions
Academy · Research Promotion · Audience-Specific Formats
Adapting Scientific Slide Decks for Regulatory, Congress and Investor Audiences: Consistency, Disclosure and Traceability
The scope of GPP2022 names meeting presentations as one of several formats — together with manuscripts, posters, abstracts and plain-language summaries — that share a single ethics and accountability standard. For this reason, the same underlying scientific content can be adapted for regulatory, congress and investor audiences without the facts themselves changing.
A scientific slide deck built for a regulatory audience, a congress audience and an investor audience will differ substantially in structure and emphasis, but under GPP2022's standard the underlying facts, data integrity and sourcing cannot change between versions; only the framing, depth and vocabulary appropriate to each audience's informational needs and obligations may change. Treating the material as a single accountable content base adapted for distinct audiences, rather than as three unrelated documents written independently, keeps the versions consistent and guards against the same claim or data point being represented differently to different readers.
Learning objectives
- Why the explicit multi-format scope of GPP2022 provides the basis for adapting a single content base across audiences
- The elements that may change, and those that must not, between a congress deck and a regulatory deck
- Why an investor-facing deck carries disclosure obligations that a deck for a scientific audience does not
Common misconceptions
- “A deck built for investors or regulators can simplify or adjust the underlying data to fit the audience's expectations.” GPP2022 treats manuscripts, meeting presentations, posters, abstracts and plain-language summaries as a single category of company-sponsored biomedical communication bound by the same principles of accuracy and transparency; the underlying data and claims must therefore remain consistent across every audience-specific version, and only framing, depth and vocabulary should be adapted.
A single accountable content base for all audience-specific versions
GPP2022's scope explicitly groups "manuscripts, meeting presentations, posters, abstracts, and plain-language summaries" together as formats sharing one ethics, data-integrity, and accountability standard, which is the basis for treating a congress deck, a regulatory submission deck, and an investor-facing deck as different presentations of a single accountable content base rather than as independently written documents1. Every version should trace back to the same underlying, sourced data set, consistent with the traceability that the ICMJE (International Committee of Medical Journal Editors) expects of manuscript text, so that a reader comparing the congress and investor versions finds consistent facts presented at different levels of technical depth rather than contradictory claims2.
Permissible and impermissible differences between congress and regulatory decks
A congress or scientific-meeting deck is built around the specific abstract and data accepted by the meeting, written for an audience with substantial scientific literacy, and focused on a defined scientific question. A regulatory-facing deck, by contrast, typically supports a specific regulatory interaction and must present the full data set relevant to that interaction, including limitations and safety considerations, in a structure that matches the format expected by the regulatory body rather than a scientific-meeting narrative. What changes between the two is organization, depth and the parts of the data set that are emphasized; what does not change is the underlying data, its sourcing, and the disclosure of funding and contributor involvement that both GPP2022 and the guidance of COPE (the Committee on Publication Ethics) on medical-communications-company involvement require regardless of audience15.
Disclosure obligations specific to investor-facing decks
An investor-facing scientific deck carries an additional obligation that the other two versions do not: it is read by an audience making financial decisions based partly on how clinical or scientific progress is framed. The disclosure and accountability principles that GPP2022 sets for scientific accuracy therefore sit alongside separate financial-disclosure obligations, which fall outside GPP2022's own scope but are not optional merely because the deck also serves a scientific communication purpose. In practice, an investor-facing version of a scientific slide deck requires its own dedicated review by those responsible for financial-disclosure compliance, in addition to, not instead of, the subject-matter expert and medical/compliance review that the underlying scientific content already requires under GPP2022's standard1. Treating the investor version merely as a less technical variant of the congress deck, without this additional review, overlooks the distinct obligation that this audience introduces.
Traceability of all audience-specific versions to a common source
The most practical means of keeping congress, regulatory and investor versions of a scientific slide deck consistent is to maintain a single master reference-mapping document that maps every claim or figure in every version to its original source, consistent with the sourcing traceability ICMJE expects of manuscript text2. Any contributor named in multiple versions should have their involvement and affiliation disclosed consistently in each, applying the disclosure logic that COPE's medical-communications-company case recommended for a single document across every version of the same underlying content5. A documented review trail showing which version was reviewed by whom, and confirming that no version diverges from the underlying sourced data set, provides concrete evidence that the content base, and not only its presentation, has remained consistent across every audience for which it was adapted.
Coordination across medical, regulatory and investor-relations functions
Because a single content base supplies versions reviewed by distinct functions (medical affairs or scientific review for the congress and regulatory versions, and often a separate investor-relations or legal team for the investor version), coordinating these reviewers around the same source material is itself a distinct project task rather than something that occurs automatically. A practical approach is to designate one person or small group as owner of the master reference-mapping document described above, and to require every functional reviewer to flag any proposed change against that master rather than editing the data in their own version independently2. Without a single point of coordination, it is possible, even with good intentions on the part of every team, for a clarification requested by a regulatory reviewer never to reach the team maintaining the congress version, leaving the two decks subtly inconsistent although each has been properly reviewed by its own function. Treating this coordination role as a named responsibility, rather than an informal expectation that reviewers will communicate with one another, is what maintains the consistency of the underlying content in practice across every audience it reaches.
This coordination challenge tends to increase as a product progresses through its lifecycle and accumulates more audience-specific versions, built at different times by different project teams, some of which may be unaware that earlier versions exist. A practical safeguard against such drift is a simple, centrally accessible registry listing every audience-specific version of a given scientific content base, its owner, and the date on which it was last reconciled against the master reference-mapping document. Without such a registry, an organization can lose track of how many versions of a given deck exist across its regulatory affairs, medical affairs and investor-relations functions, which makes it effectively impossible to guarantee consistency even if every individual version was carefully built and properly reviewed at the time of its creation.
A further consideration specific to the investor audience is timing: an investor-facing version of a scientific deck is often required on a schedule set by external events, such as an earnings call, an investor conference or a specific corporate announcement, that does not align with the timeline of a congress submission or a regulatory interaction. The investor version therefore frequently has to be prepared on a compressed schedule relative to the other versions, which makes an already-reviewed, already-sourced master content base particularly valuable; building the investor version anew under such external deadline pressure, without a reliable, pre-vetted content base to adapt, is one of the more common circumstances in which an organization omits a review step it would not otherwise omit.
Finally, organizations should expect the regulatory version to require the most lead time of the three, since the schedule of a regulatory interaction is typically set by the regulatory body rather than by the organization, and the depth of data and disclosure of limitations expected by a regulatory audience is generally the most extensive of the three versions. Treating the regulatory version as the anchor that determines the earliest point at which the full underlying content base must be finalized, with the congress and investor versions then adapted from that finalized base, is a practical sequencing principle that keeps all three versions aligned to the same fully vetted source.
Organizations that manage this process effectively tend to establish the sequencing expectation when briefing every function at the outset, informing the regulatory, congress and investor-relations teams which version anchors the schedule and why, rather than allowing each team to assume independently that its own version sets the pace. This single piece of early communication prevents a common and avoidable conflict in which two functions each believe that their own deadline should take priority because no one informed them in advance which version the underlying content base was being built around.
Key points
Key points
Because GPP2022 treats meeting presentations as one of several formats sharing a single accountability standard, a congress, regulatory or investor-facing scientific slide deck should be regarded as one accountable content base adapted in framing and depth for each audience, with the underlying data, sourcing and disclosure obligations held constant across every version.
Practical application
Practical application
- A single master reference-mapping document should be maintained across every audience-specific version. Every version should trace its claims to the same sourced data set, so that inconsistencies between versions are identified immediately rather than discovered later.
- An investor-facing version should undergo financial-disclosure review in addition to scientific review. This is a distinct obligation that the congress and regulatory versions do not carry, and it should not be assumed to be covered by scientific review alone.
- The involvement of every contributor should be disclosed consistently across all versions. The disclosure standard that COPE’s guidance for medical communications companies recommends for a single document should apply uniformly across the congress, regulatory and investor versions of the same content.
Frequently asked questions
No; GPP2022's standard requires the same data integrity and accuracy across every format it covers, so only framing, depth, and vocabulary should differ between audience-specific versions, not the underlying facts.
It requires an additional review for financial-disclosure compliance alongside, not instead of, the subject-matter expert and medical/compliance review that the scientific content already requires.
By maintaining a single master reference-mapping document that every version's claims trace back to, and a documented review trail confirming no version diverges from the underlying sourced data set.
References
- DeTora LM, Toroser D, Sykes A, et al. Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Annals of Internal Medicine. 2022. read 10 October 2026. View on Annals of Internal Medicine
- International Committee of Medical Journal Editors (ICMJE). Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. read 10 October 2026. View ICMJE Recommendations
- International Society for Medical Publication Professionals (ISMPP). Certified Medical Publication Professional (CMPP) Certification Overview. read 10 October 2026. View on ISMPP
- International Society for Medical Publication Professionals (ISMPP). CMPP Code of Conduct. read 10 October 2026. View ISMPP Code of Conduct
- Committee on Publication Ethics (COPE). Authors' contributions and the involvement of a medical communications company. COPE Case 14-07. read 10 October 2026. View on COPE
- American Medical Writers Association (AMWA). 2024 Compensation Survey: Freelance and Employed Medical Communicators Infographic. read 10 October 2026. View AMWA 2024 Compensation Infographic
- U.S. Department of Health and Human Services, Office for Civil Rights. HIPAA Privacy Rule and Research. read 10 October 2026. View on HHS.gov
- Eaton L. Medical editors issue guidance on ghost writing. BMJ. 2005;330(7498):988. read 10 October 2026. View on The BMJ
- European Medical Writers Association (EMWA). 2022 update to Good Publication Practice Guidelines for Company-Sponsored Biomedical Research. Medical Writing. 2022;31(3). read 10 October 2026. View on EMWA
- International Society for Medical Publication Professionals (ISMPP). Mission and Vision. read 10 October 2026. View on ISMPP
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 10). Adapting Scientific Slide Decks for Regulatory, Congress and Investor Audiences: Consistency, Disclosure and Traceability. Pubrica. https://pubrica.com/academy/scientific-slide-deck-content-team/
Pubrica Academy. “Adapting Scientific Slide Decks for Regulatory, Congress and Investor Audiences: Consistency, Disclosure and Traceability.” Pubrica, 10 Oct. 2026, pubrica.com/academy/scientific-slide-deck-content-team/.
Pubrica Academy (2026) Adapting Scientific Slide Decks for Regulatory, Congress and Investor Audiences: Consistency, Disclosure and Traceability. Pubrica. Available at: https://pubrica.com/academy/scientific-slide-deck-content-team/ (Accessed: 15 October 2026).
Pubrica Academy. “Adapting Scientific Slide Decks for Regulatory, Congress and Investor Audiences: Consistency, Disclosure and Traceability.” Pubrica. October 10, 2026. https://pubrica.com/academy/scientific-slide-deck-content-team/
Pubrica Academy, ‘Adapting Scientific Slide Decks for Regulatory, Congress and Investor Audiences: Consistency, Disclosure and Traceability’ (Pubrica, 10 October 2026) <https://pubrica.com/academy/scientific-slide-deck-content-team/> accessed 15 October 2026.
Pubrica Academy. Adapting Scientific Slide Decks for Regulatory, Congress and Investor Audiences: Consistency, Disclosure and Traceability. [Internet]. Pubrica; 2026 Oct 10 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/scientific-slide-deck-content-team/
Pubrica Academy, “Adapting Scientific Slide Decks for Regulatory, Congress and Investor Audiences: Consistency, Disclosure and Traceability,” Pubrica, Oct. 10, 2026. [Online]. Available: https://pubrica.com/academy/scientific-slide-deck-content-team/
@misc{/la_slide_deck_regulatory_congress_investor_formats_2026,
author = {{Pubrica Academy}},
title = {Adapting Scientific Slide Decks for Regulatory, Congress and Investor Audiences: Consistency, Disclosure and Traceability},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/scientific-slide-deck-content-team/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Multi-Audience Slide Deck Consistency Checklist
This checklist may be used when adapting a single scientific content base for regulatory, congress and investor audiences.
[ ] Confirmed every version traces back to the same master reference-mapping document [ ] Verified no audience-specific version alters the underlying data or claims [ ] Routed the investor-facing version through financial-disclosure review separately [ ] Disclosed every contributor's involvement consistently across all versions [ ] Documented which version was reviewed by whom, and when
Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica develops scientific slide decks from a single accountable content base and adapts framing and depth for regulatory, congress and investor audiences, keeping every version traceable to the same sourced data and disclosure record.